Cost-effectiveness of H. pylori eradication.
Roesch
W
W
Department of Medicine, Northwest-Hospital Frankfurt am Main, Germany.
D000658:Amoxicillin / Q000191:economics / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000191:economics* / Q000627:therapeutic use; D017291:Clarithromycin / Q000191:economics / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000191:economics; D016481:Helicobacter Infections / Q000188:drug therapy / Q000191:economics*; D016480:Helicobacter pylori; D006801:Humans; D008390:Markov Chains; D009853:Omeprazole / Q000191:economics / Q000627:therapeutic use; D010406:Penicillins / Q000191:economics / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy / Q000191:economics*; D013274:Stomach Neoplasms / Q000191:economics / Q000517:prevention & control; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D010406:Penicillins; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole